Madhav V. Dhodapkar, MBBS

Arthur H. Bunker and Isabel Bunker Professor of Medicine (Hematology) and Professor of Immunobiology; Chief, Section of Hematology, Department of Internal Medicine; Disease Aligned Research Team Leader, Hematology Program, Yale Cancer Center

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Hematology

Cancer Center: Hematology Program

Lysosomal Disease & Inherited Metabolic Liver Disease Program

Yale Medicine

Office of Cooperative Research

Board Certifications

  • Hematology (Internal Medicine) AB of Internal Medicine (1994)

  • Medical Oncology AB of Internal Medicine (1995)

Clinical Trials

Conditions Study Title
Multiple Myeloma An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma- CheckMate 602: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 602
Multiple Myeloma A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Dexamethasone in Patients With Multiple Myeloma Exposed to Bortezomib, Carfilzomib, Lenalidomide and Pomalidomide and Refractory to an IMiD and a Proteasome Inhibitor
Leukemia, other Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
Genetics - Adult, Immune System The Human Microbiome in Immune-Mediated Diseases
Hodgkin's Lymphoma, Leukemia, other, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Hematopoietic, Phase I An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
Multiple Myeloma A Study of MPDL3280A (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) Administered With or Without Lenalidomide in Patients With Multiple Myeloma (MM)
Multiple Myeloma Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma
Multiple Myeloma Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Edit this profile

Contact Info

Madhav V. Dhodapkar, MBBS
Patient Care Location
Yale Cancer CenterYale-New Haven Hospital
20 York Street, Ste North Pavillion 7

New Haven, CT 06510
View on map...
Lab Location
Dhodapkar LabSterling Hall of Medicine, I-Wing
333 Cedar Street, Wing I Fl 2 Rm 245

New Haven, CT 06510
View on map...
Mailing Address
PO Box 208028
333 Cedar Street, TMP 3

New Haven, CT 06520-8028